AstraZeneca plc, one of the world’s largest pharmaceutical and biotechnology companies, was founded in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group. Today, AstraZeneca CEO Sir Pascal Soriot leads the company’s $58.7 billion business and a global workforce of over 89,000 employees across more than 100 countries. Appointed in October 2012, Soriot — a French-Australian veterinarian-turned-pharma-executive with an MBA from HEC Paris — has transformed AstraZeneca from a struggling mid-tier player into one of the world’s top five pharmaceutical companies. He famously rebuffed Pfizer’s $118 billion hostile takeover bid in 2014, led the AstraZeneca-Oxford COVID-19 vaccine partnership, and was knighted in 2022 for his services to life sciences. Under his leadership, AstraZeneca reported full-year 2025 revenue of $58.7 billion and is targeting $80 billion by 2030.

(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Pascal Soriot – Quick Facts

AstraZeneca Competitors

AstraZeneca operates in the highly competitive global pharmaceutical and biotechnology industry. The key competitors of AstraZeneca include:

• Pfizer – Global pharmaceutical leader in vaccines and oncology
• Roche / Genentech – World leader in oncology and diagnostics
• Novartis – Swiss pharma giant with strength in oncology and gene therapy
• Johnson & Johnson – Diversified healthcare conglomerate
• Merck & Co. – Leader in immunology and oncology (Keytruda)
• Bristol-Myers Squibb – Strong presence in immuno-oncology
• GSK (GlaxoSmithKline) – UK rival in respiratory and infectious disease
• Eli Lilly – Rapidly growing in diabetes, obesity, and neuroscience

Early Life & Education

Pascal Claude Roland Soriot was born on May 23, 1959, in France. Growing up, his father died when he was just 20 years old. He has three brothers, all of whom became doctors. Soriot took a different path, studying veterinary medicine at the prestigious École nationale vétérinaire d’Alfort near Paris, one of the oldest veterinary schools in the world. He earned his Doctor of Veterinary Medicine degree — an unusual background that gave him a deep scientific foundation that many pharma CEOs with pure business backgrounds lack.

Seeking to move into the business world, Soriot later completed an MBA at HEC Paris, one of Europe’s most elite business schools. This combination of scientific and business training would prove invaluable throughout his career in the pharmaceutical industry.

Career & Rise to CEO

Pascal Soriot entered the pharmaceutical industry in 1986, joining Roussel Uclaf as a pharmaceutical sales representative in Australia. His career spanned multiple continents and some of the biggest names in pharma over the next two-and-a-half decades.

Pascal Soriot Career Timeline

After starting at Roussel Uclaf in Australia, Soriot moved through the pharmaceutical industry’s major consolidations — from Hoechst to Sanofi and Aventis, where he held senior management positions across multiple continents. He then joined Hoffmann-La Roche, where he rose to become CEO of the pharmaceutical division and later managed Genentech in California. By 2010, he was serving as Chief Operating Officer of Roche’s Pharmaceuticals Division, overseeing one of the largest pharma businesses in the world.

On August 28, 2012, AstraZeneca announced Soriot as its new CEO. He took up the post on October 1, 2012 — inheriting a company facing patent cliffs, a thin pipeline, and falling revenues. What followed was one of the most dramatic turnarounds in pharmaceutical history.

(Related: Novartis CEO Email & Net Worth – Vas Narasimhan Salary)

AstraZeneca CEO Role – Leadership & Achievements

Under Pascal Soriot’s leadership since 2012, AstraZeneca has been transformed from a company in decline into a global pharmaceutical powerhouse. Key milestones include:

• Pfizer Takeover Rejection (2014): Soriot famously rejected Pfizer’s $118 billion hostile takeover bid, a decision that proved spectacularly right as AstraZeneca’s market cap has since grown to over $200 billion.
• Oncology Dominance: Built AstraZeneca into a top-tier oncology company, with blockbusters like Tagrisso, Imfinzi, Enhertu, and Lynparza. The company now has 16 blockbuster medicines.
• COVID-19 Vaccine (2020–2021): Led the partnership with Oxford University to develop one of the first COVID-19 vaccines, delivering over 3 billion doses worldwide on a not-for-profit basis during the pandemic.
• Knighthood (2022): Awarded Knight Commander of the Order of the British Empire (KBE) for services to UK life sciences and COVID-19 leadership.
• Revenue Growth: Grew AstraZeneca’s revenue from ~$25 billion in 2012 to $58.7 billion in 2025 — more than doubling the company’s size.
• $80 Billion Target: Set an ambitious goal to reach $80 billion in annual revenue by 2030, backed by 20+ Phase III trial readouts expected in 2026.
• NYSE Listing (2026): AstraZeneca completed a historic move to list on the New York Stock Exchange in February 2026, cementing the US as its largest market.
• SCI President’s Medal (2024): Awarded the Society of Chemical Industry’s President’s Medal for leading the COVID-19 vaccination programme.

Pascal Soriot Net Worth 2026 – AstraZeneca CEO Salary

As of 2026, Pascal Soriot’s estimated net worth is approximately $65–90 million USD, built over more than a decade of leadership at one of the world’s largest pharmaceutical companies plus significant AstraZeneca equity holdings accumulated during his tenure.

AstraZeneca CEO Compensation Breakdown (FY2025)

AstraZeneca Net Worth 2026 – Is AstraZeneca Profitable?

Yes, AstraZeneca is highly profitable and one of the most valuable pharmaceutical companies in the world. Under CEO Pascal Soriot, the company has delivered exceptional financial growth.

AstraZeneca Financial Summary (FY2025)

(Recommended: GSK CEO Email & Net Worth – Emma Walmsley Salary)

AstraZeneca CEO Email Address | Pascal Soriot Contact

Below are the official contact details and social media profiles for AstraZeneca CEO Pascal Soriot:

Pascal Soriot Wiki – Age, Family, & Personal Life

Sir Pascal Soriot (age 66) holds both French and Australian citizenship. He is married and has two children, both of whom live in Australia. His wife reportedly spends four months a year in Australia to be near their family. Soriot keeps his personal life notably private for someone in such a prominent position.

Soriot’s father died when he was 20, and he has three brothers — all of whom became doctors. His own path as a veterinarian-turned-pharma-CEO is one of the most unconventional in the industry. Outside of work, he has an interest in modern art and supports philanthropic causes in global health and education.

Notable Achievements & Recognitions

• Knight Commander of the Order of the British Empire (KBE) – Knighted in 2022 for services to UK life sciences and COVID-19 leadership
• SCI President’s Medal (2024) – Awarded by the Society of Chemical Industry for leading the COVID-19 vaccination programme
• World Economic Forum Speaker – Regular panelist at Davos
• Longest-Serving Major Pharma CEO – 13+ years leading AstraZeneca, longest tenure among top-5 pharma CEOs
• COVID-19 Vaccine Legacy – Led the Oxford-AstraZeneca vaccine effort delivering 3+ billion doses worldwide on a not-for-profit basis
• Pfizer Takeover Defence – His 2014 rejection of Pfizer’s $118B bid is now studied in business schools as one of the best M&A defence decisions in corporate history

Fun Fact

Pascal Soriot trained as a veterinarian before entering the pharmaceutical industry. He started his pharma career as a sales rep in Australia in 1986 and worked his way up over three decades to run one of the world’s largest drug companies. His scientific training as a vet gives him an unusual ability to engage deeply with AstraZeneca’s R&D pipeline — something analysts and scientists at the company have frequently praised.

About AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK. The company was formed in 1999 through the merger of Astra AB (Sweden) and Zeneca Group (UK). AstraZeneca focuses on three main therapy areas:

AstraZeneca trades on both the London Stock Exchange and the New York Stock Exchange under the ticker AZN. In February 2026, the company completed a historic primary listing on the NYSE, cementing the US as its largest market. The company operates in over 100 countries with approximately 89,000 employees.

Frequently Asked Questions (FAQ)

Article last updated:February 2026March 4, 2026